Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study
- Details
- Category: AstraZeneca

In this study, Evusheld's Inhibitory Concentration 50 (IC50), a measure of neutralising potency of an antibody, was 171 ng/ml and 277 ng/ml in two confirmatory tests, which is within the range of neutralising titres found in someone who has been previously infected with COVID-19.
Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
- Details
- Category: Novartis

Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
- Details
- Category: GlaxoSmithKline

EUR 50 million for social businesses - Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements
- Details
- Category: Boehringer Ingelheim

Pfizer and BioNTech provide update on Omicron variant
- Details
- Category: Pfizer

Roche completed the repurchase of Roche shares from Novartis
- Details
- Category: Roche

GSK and the University of Oxford launch new Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease
- Details
- Category: GlaxoSmithKline

More Pharma News ...
- AWS helps Pfizer accelerate drug development and clinical manufacturing
- GSK unveils Target the Future, a global, multi-year programme to help address key challenges affecting the multiple myeloma community
- Sanofi invests $180 million equity in Owkin's artificial intelligence and federated learning to advance oncology pipeline
- Pfizer and BioNTech receive expanded U.S. FDA emergency use suthorization of COVID-19 vaccine booster to include individuals 18 and older
- GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment
- Pfizer to provide U.S. government with 10 million treatment courses of investigational oral antiviral candidate to help combat COVID-19
- Two billion doses of AstraZeneca’s COVID-19 vaccine supplied to countries across the world